EksoNR

Overview and Use Cases

The EksoNR is a wearable, powered exoskeleton designed for use in inpatient and outpatient neurological rehabilitation settings. It is worn over the patient's clothing and attaches at the hips, thighs, and lower legs, providing motorized assistance to the hip and knee joints during walking. The primary patient populations include:

• Stroke survivors seeking to regain functional gait
• Acquired brain injury (ABI) patients in sub-acute or chronic recovery phases
• Multiple sclerosis (MS) patients with lower-limb weakness or spasticity
• Spinal cord injury (SCI) patients, including those with incomplete injuries

The device is intended for use by trained rehabilitation therapists in clinical environments rather than for independent home use.

Key Technical Features

The EksoNR incorporates several features aimed at maximizing therapeutic value:

• SmartAssist™ technology: Allows clinicians to set different levels of assistance independently for each leg, enabling the device to provide more support to the weaker limb while encouraging the stronger limb to work harder.
• Real-time feedback: An onboard software interface provides therapists with session data, including step count, weight-shifting metrics, and assistance levels, supporting data-driven therapy decisions.
• Adjustable fit: The exoskeleton is designed to accommodate a range of patient body sizes, though specific height and weight parameters should be confirmed with Ekso Bionics for the most current specifications.
• Upright posture support: The system promotes a natural, upright walking posture, which is considered beneficial for cardiovascular health and psychological well-being in addition to motor recovery.

The device is powered by an onboard battery system; session duration and battery life figures should be verified against current manufacturer documentation.

Comparison to Similar Devices

Within the rehabilitation exoskeleton market, the EksoNR competes with devices such as the ReWalk Personal (ReWalk Robotics), the Lokomat (Hocoma, a treadmill-based system), and the Indego (Parker Hannifin). Key differentiators of the EksoNR include its emphasis on over-ground walking (as opposed to treadmill-based systems), its asymmetric assistance capability via SmartAssist™, and its specific FDA clearance for neurological indications.

It is worth noting that Ekso Bionics also produces the EksoVest and other industrial exoskeleton products targeting worker ergonomics — a separate product line from the clinical rehabilitation-focused EksoNR.

Market Context and Target Buyers

The EksoNR is positioned in the premium clinical rehabilitation segment. It is typically acquired by:

• Inpatient rehabilitation hospitals
• Outpatient neurological therapy centers
• Academic medical centers and research institutions

As a capital medical device, the EksoNR is generally sold or leased directly to healthcare facilities rather than to individual patients. Pricing is not publicly listed and is typically negotiated on an institutional basis. Reimbursement pathways for exoskeleton-assisted therapy continue to evolve across different healthcare systems globally.

Deployments and Notable Adoption

As of public reporting, the EksoNR has been deployed in rehabilitation facilities across the United States, Europe, and other international markets. Ekso Bionics has reported partnerships with various hospital systems and rehabilitation networks, though specific customer names and deployment numbers should be verified against current company communications. The device has also been used in clinical research studies examining the efficacy of exoskeleton-assisted gait training for neurological populations.

Future Outlook

The broader market for rehabilitation exoskeletons is expected to grow as populations age and the incidence of stroke and neurological conditions increases globally. Ekso Bionics has indicated ongoing development efforts focused on software enhancements, expanded clinical evidence generation, and potentially broadening the indications for use. Regulatory approvals in additional international markets and evolving insurance reimbursement policies are likely to influence the pace of adoption. Integration with digital health platforms and remote monitoring capabilities may represent future development directions for the EksoNR platform.